Drugs / KC1086
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07118709 | Aug 2025 → Aug 2028 expected | — | Beijing Konruns Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KC1086 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07118709 ↗ |
| Route | Oral | “KC1086 are given orally once daily, 21 days as a cycle” NCT07118709 ↗ |